Alcon (ALC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Alcon (ALC) reported $2.59 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 6.4%. EPS of $0.79 for the same period compares to $0.81 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $2.59 billion, representing a surprise of -0.1%. The company delivered an EPS surprise of +2.6%, with the consensus EPS estimate being $0.77.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Alcon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Net Sales by region- International: $1.42 billion versus the two-analyst average estimate of $1.43 billion. The reported number represents a year-over-year change of +7.7%.Net Sales by region- United States: $1.17 billion versus $1.16 billion estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +5% change.Net Sales- Total Surgical: $1.42 billion versus the three-analyst average estimate of $1.42 billion. The reported number represents a year-over-year change of +6.1%.Net Sales- Total Vision care: $1.17 billion versus the three-analyst average estimate of $1.17 billion. The reported number represents a year-over-year change of +6.8%.Net Sales- Total Surgical- Consumables: $745 million compared to the $743.89 million average estimate based on three analysts. The reported number represents a change of +6.3% year over year.Net Sales- Total Surgical- Equipment/other: $243 million compared to the $245.51 million average estimate based on three analysts. The reported number represents a change of +13% year over year.Net Sales- Total Vision Care- Contact lenses: $707 million versus $724.58 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6.5% change.Net Sales- Total Vision Care- Ocular health: $462 million versus the three-analyst average estimate of $448.6 million. The reported number represents a year-over-year change of +7.2%.Net Sales- Total Surgical- Implantables: $432 million compared to the $430 million average estimate based on three analysts. The reported number represents a change of +2.4% year over year.Net Sales and other revenues- Other revenues: $25 million versus $19.52 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +19.1% change.View all Key Company Metrics for Alcon here>>>Shares of Alcon have returned +2.5% over the past month versus the Zacks S&P 500 composite's +4.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alcon (ALC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks